Treatment of Functional Dyspepsia

Diagnostic Approach

The American Gastroenterological Association recommends that a full blood count should be performed in patients ≥55 years with dyspepsia and coeliac serology in patients with overlapping IBS-type symptoms 1
Urgent endoscopy is warranted in patients ≥55 years with weight loss, or those >40 years from high-risk areas for gastric cancer or with family history of gastro-oesophageal cancer 1
Non-urgent endoscopy should be considered in patients ≥55 years with treatment-resistant dyspepsia or dyspepsia with raised platelet count, nausea, or vomiting 1
Urgent abdominal CT scanning should be considered in patients ≥60 years with abdominal pain and weight loss to exclude pancreatic cancer 1

First-Line Treatment

The European Society for Gastrointestinal Motility recommends that all patients with FD should be offered non-invasive testing for Helicobacter pylori ("test and treat") and, if infected, given eradication therapy 1, 2
Regular aerobic exercise is recommended for all patients with FD 1
Patients without H. pylori infection should be offered empirical acid suppression therapy 1
Proton pump inhibitors (PPIs) are effective for FD, especially for epigastric pain syndrome (EPS) subtype, using the lowest effective dose 1

Second-Line Treatment

Tricyclic antidepressants at low doses are recommended as second-line therapy, particularly for EPS 2
Patients should avoid foods that trigger symptoms while being cautious not to adopt overly restrictive diets that could lead to malnutrition 3, 2
There is insufficient evidence to recommend specialized diets, including low FODMAP diets, for FD 1

Management of Refractory Cases

Referral to gastroenterology is appropriate when there is diagnostic doubt, symptoms are severe or refractory to first-line treatments 1
Patients with severe symptoms that don't respond to standard treatments should be managed by a multidisciplinary team including primary care physicians, dietitians, gastroenterologists, and psychologists 3, 2
Combination therapies may be considered, such as dual therapy with different medication classes 2

Treatment Algorithm Based on Symptom Subtype

For all patients: Test for H. pylori and eradicate if positive 1, 2
For EPS (predominant epigastric pain): First line: PPI or H2 receptor antagonist 1
For PDS (predominant fullness, bloating, early satiety): First line: Prokinetic agent 1

Common Pitfalls and Caveats

Avoid prescribing overly restrictive diets that may lead to malnutrition or abnormal eating habits 3, 2
Be aware that gastric emptying testing or 24-hour pH monitoring should not be routinely performed in patients with typical FD symptoms 1
Avoid using cinitaprida with other medications that may prolong the QT interval 2

Treatment of Functional Dyspepsia

Diagnosis and First-Line Treatment

All patients with dyspepsia should undergo H. pylori testing and receive eradication therapy if positive, as recommended by the British Society of Gastroenterology and American Gastroenterological Association 4, 5
The British Society of Gastroenterology guidelines establish a clear treatment hierarchy that does not include levosulpiride as first-line therapy, instead prioritizing H. pylori eradication and PPI therapy 4, 5

Second-Line and Alternative Treatments

Levosulpiride could be considered after H. pylori eradication and PPI trial have failed to provide adequate symptom relief, particularly for patients with predominant dysmotility-like symptoms 6
The American Gastroenterological Association recommends tricyclic antidepressants at low doses as second-line therapy for functional dyspepsia, particularly for epigastric pain syndrome, but this is not directly cited in the provided text, however, levosulpiride may be an alternative prokinetic agent in certain cases 6

Safety and Clinical Algorithm

Recognize that cisapride is no longer recommended due to cardiac toxicity, and avoid combining levosulpiride with medications that prolong the QT interval, as per the British Society of Gastroenterology guidelines 6
A clinical algorithm for managing functional dyspepsia involves testing for H. pylori, eradication if positive, trial of PPI therapy, and consideration of prokinetic agents like levosulpiride or low-dose tricyclic antidepressants if symptoms persist, as outlined by the British Society of Gastroenterology and American Gastroenterological Association 4, 5, 6

Management of Functional Dyspepsia

Initial Diagnosis and Assessment

Diagnose functional dyspepsia clinically in patients with bothersome epigastric pain or burning, early satiation, and/or postprandial fullness lasting >8 weeks, without alarm symptoms 7

First-Line Treatment Algorithm

All H. pylori-positive patients must receive eradication therapy as the initial intervention, regardless of symptom subtype, which provides modest but meaningful symptom improvement in functional dyspepsia 7

Management of Severe or Refractory Cases

Patients with severe refractory symptoms require management by a team including primary care physicians, dietitians, gastroenterologists, and psychologists 8, 9
Screen patients with severe FD presenting with weight loss and food restriction for eating disorders and disordered eating, including avoidant restrictive food intake disorder (ARFID) 8, 9
Refer to dietitian early in refractory cases to prevent overly restrictive diets 8, 9

Critical Safety Warnings

Avoid opioids and surgery in patients with severe or refractory functional dyspepsia to minimize iatrogenic harm 8

Doctor-Patient Communication

Establish an empathic relationship and explain that functional dyspepsia is a disorder of gut-brain interaction, not a psychological condition or "all in their head" 7
Discuss the underlying pathophysiology, natural history, and common symptom triggers to improve quality of life and reduce healthcare utilization 7

Management of Functional Dyspepsia

Diagnosis and Treatment

The American Gastroenterological Association recommends that all patients with dyspepsia should be evaluated for Helicobacter pylori using non-invasive tests and receive eradication therapy if positive, followed by empirical acid suppression with proton pump inhibitors (PPIs) if negative or if symptoms persist after eradication 10
The European Society of Gastrointestinal Motility recommends avoiding cisapride due to cardiac toxicity 11
The American College of Gastroenterology recommends that antidepressants, particularly tricyclic antidepressants at low doses, are the most effective second-line treatment for functional dyspepsia, especially for epigastric pain syndrome 12

Multidisciplinary Management

A multidisciplinary team including primary care physicians, dietitians, gastroenterologists, and psychologists is mandatory for managing refractory or severe cases of functional dyspepsia 12
Early referral to a dietitian is recommended to prevent excessively restrictive diets 12

Patient Education and Communication

Establishing an empathetic relationship and explaining the underlying pathophysiology, natural history, and common symptom triggers of functional dyspepsia can reduce healthcare utilization and improve quality of life 10, 12
The American Gastroenterological Association recommends discussing the fact that functional dyspepsia is a brain-gut interaction disorder, not a psychological condition or "all in their head" 12

Safety Precautions

Opioids and surgery should be avoided in patients with severe or refractory functional dyspepsia to minimize iatrogenic harm 12
Excessively restrictive diets that can lead to malnutrition or eating disorders should be avoided 12
Cisapride should be avoided due to cardiac toxicity 11

Management of Dyspepsia with Predominantly Bloating

Initial Treatment Approach

The American Gastroenterological Association recommends a prokinetic agent as the preferred first-line symptomatic therapy for dyspepsia with predominantly bloating and fullness after H. pylori testing and eradication if positive 13

Treatment Algorithm for Bloating-Predominant Dyspepsia

If prokinetic therapy fails, switch to a different treatment class, specifically trial full-dose PPI therapy for 4-8 weeks, as patients may have been misclassified and could have acid-related symptoms 13
If symptoms persist after switching from prokinetic to PPI, consider high-dose PPI therapy before proceeding to endoscopy 13

Key Distinction from Other Dyspepsia Subtypes

The management of bloating-predominant dyspepsia differs significantly from ulcer-like dyspepsia, where full-dose PPI therapy is the first-line symptomatic treatment, and for bloating-predominant symptoms, prokinetic agents are the rational first choice after addressing H. pylori 13

Pharmacological Treatment of Functional Dyspepsia

First-Line Treatment Algorithm

All patients with functional dyspepsia should first undergo non-invasive H. pylori testing and receive eradication therapy if positive, followed by empirical acid suppression with proton pump inhibitors (PPIs) if symptoms persist, as recommended by the American Gastroenterological Association 14

Second-Line Treatment

Tricyclic antidepressants (TCAs) are the most effective second-line therapy, particularly for refractory Epigastric Pain Syndrome (EPS), with a starting dose of 10 mg once daily at bedtime, as recommended by the American Gastroenterological Association 14
Alternative second-line agents include antipsychotics such as sulpiride 100 mg four times daily or levosulpiride 25 mg three times daily, which requires careful explanation of rationale and counseling about side effects, as recommended by the American Gastroenterological Association 14

Treatment Algorithm by Symptom Subtype

For EPS, amitriptyline 10 mg at bedtime, titrated to 30-50 mg daily, is recommended for inadequate response to PPI therapy, as recommended by the American Gastroenterological Association 14
For Postprandial Distress Syndrome (PDS), amitriptyline 10 mg at bedtime, titrated to 30-50 mg daily, is recommended if prokinetic agents fail, as recommended by the American Gastroenterological Association 14

Management of Refractory or Severe Cases

A multidisciplinary team including primary care physicians, dietitians, gastroenterologists, and psychologists is mandatory for severe or refractory functional dyspepsia, as recommended by the American Gastroenterological Association 14
Combination therapies, such as TCA + PPI, may be considered for augmentation effects in refractory cases, as recommended by the American Gastroenterological Association 14

Critical Safety Warnings and Pitfalls

Opioids should never be prescribed for functional dyspepsia due to iatrogenic harm without benefit, as warned by the American Gastroenterological Association 14
Cisapride should be avoided due to fatal cardiac arrhythmias and QT prolongation, as warned by the American Gastroenterological Association 15, 16

Treatment of Dyspepsia Without Anxiety or Depression

First-Line Management Algorithm

The initial treatment approach for functional dyspepsia without anxiety or depression should be H. pylori "test and treat" using non-invasive testing, followed by empirical proton pump inhibitor therapy if H. pylori is negative or symptoms persist after eradication, as recommended by the American Gastroenterological Association 17
All patients with dyspepsia should undergo non-invasive H. pylori testing as the initial intervention, regardless of symptom subtype, with a strength of evidence level of high 17
Use 13C urea breath test or stool antigen test for H. pylori testing, as they have higher specificity compared to serology, according to the American College of Gastroenterology 18, 19
If H. pylori is positive, provide eradication therapy immediately, as this cures underlying peptic ulcer disease and prevents future gastroduodenal complications, with a strength of evidence level of high 18, 17
Do not perform repeat testing after eradication in primary care functional dyspepsia, as most patients will not achieve symptom resolution from H. pylori treatment alone, as stated by the National Institute for Health and Care Excellence 17

Empirical Acid Suppression

Initiate full-dose PPI therapy for 4-8 weeks, particularly effective for epigastric pain syndrome subtype, with a strength of evidence level of moderate 17, 20
PPIs are superior to H2-receptor antagonists, antacids, and placebo for symptom relief in dyspepsia, according to the American College of Gastroenterology 21, 18, 20

Important Context

The "test and treat" strategy reduces the relative risk of remaining symptomatic at 12 months and significantly decreases endoscopy requirements compared to other strategies, with a strength of evidence level of high 17
H. pylori eradication provides symptom relief in only a minority of functional dyspepsia patients within one year, though it eliminates peptic ulcer mortality risk and prevents future gastroduodenal disease, as stated by the Centers for Disease Control and Prevention 18, 19

Management of Functional Dyspepsia in Chronic Kidney Disease

Diagnostic Approach

All patients with functional dyspepsia, including those with chronic kidney disease (CKD), should undergo non‑invasive Helicobacter pylori testing as the first diagnostic step. [22][23]
In H. pylori‑positive individuals, eradication therapy (standard triple regimen) is effective for symptom relief, although adverse events occur more frequently than with placebo or no treatment. [22][23]

First‑Line Pharmacologic Treatment

Proton‑pump inhibitors (PPIs) are recommended as the first‑line medication for functional dyspepsia in CKD patients, using the lowest effective dose to control symptoms. [22][23]
PPIs show particular efficacy for the epigastric pain‑syndrome subtype and are generally well tolerated. [22][24]
H₂‑receptor antagonists may be used as an alternative first‑line option; evidence for their efficacy is weaker than for PPIs. [22][23]

Second‑Line Pharmacologic Treatment

Tricyclic antidepressants (TCAs) constitute an evidence‑based second‑line therapy for refractory functional dyspepsia in CKD patients. [22][23]24
Amitriptyline can be initiated at 10 mg once nightly and titrated slowly to a maximum of 30–50 mg daily, based on symptom response and tolerability. [22][23]24
Patients should receive clear counseling on the gut‑brain neuromodulatory rationale and potential side‑effects when TCAs are prescribed. [22][23]
Antipsychotic agents such as sulpiride (100 mg four times daily) or levosulpiride (25 mg three times daily) may provide additional symptom relief in refractory cases, with appropriate counseling about risks. [22][24]

Lifestyle and Non‑Pharmacologic Interventions

Regular aerobic exercise is advised for all CKD patients with functional dyspepsia to improve gastrointestinal symptoms and overall health. [22][23]
Overly restrictive diets should be avoided to prevent malnutrition or eating‑disorder development, a particular concern in CKD. 24
Early involvement of a dietitian is recommended for patients with refractory dyspepsia to ensure nutritional adequacy while limiting unnecessary food restrictions. 24

Multidisciplinary Care and Safety

A multidisciplinary team—including primary‑care physicians, dietitians, gastroenterologists, and psychologists—is mandatory for managing severe or refractory functional dyspepsia in CKD patients. 24
Opioids and surgical interventions should be avoided in severe or refractory cases to minimize iatrogenic harm. 24
Routine gastric emptying studies or 24‑hour pH monitoring are not recommended for patients presenting with typical functional dyspepsia symptoms. [22][23]

Referral and Investigation Guidelines

Refer to gastroenterology when diagnostic uncertainty exists, symptoms are severe or refractory to first‑line therapy, or the patient requests specialist input. [22][23]
Consider non‑urgent endoscopy for patients aged ≥ 55 years with treatment‑resistant dyspepsia or dyspepsia accompanied by elevated platelet count, nausea, or vomiting. [22][23]
Urgent abdominal CT scanning should be contemplated for patients aged ≥ 60 years presenting with abdominal pain and weight loss to exclude pancreatic malignancy. [22][23]

Hospitalized Patient Management of Dyspepsia

Diagnostic Testing

All patients with dyspepsia should undergo non‑invasive Helicobacter pylori testing using a urea breath test or stool antigen assay (serology is less specific) to guide therapy. 25
When H. pylori infection is identified, eradication therapy should be administered, which has strong evidence of efficacy for symptom resolution. 26

Indications for Urgent Endoscopy

Presence of alarm features—dysphagia, gastrointestinal bleeding, anemia, or unintentional weight loss—warrants prompt endoscopic evaluation. 25

First‑Line Pharmacotherapy

Proton‑pump inhibitors (PPIs) remain the preferred first‑line agents for inpatient dyspepsia; H₂‑receptor antagonists can be used as alternatives, although the supporting evidence for efficacy is weaker than that for PPIs. 26

Second‑Line Pharmacotherapy

Low‑dose tricyclic antidepressants (TCAs) are the most effective second‑line treatment for epigastric pain syndrome in patients who do not respond to PPIs. 26
A typical low‑dose TCA regimen starts with amitriptyline 10 mg taken at bedtime and is titrated slowly to a maximum of 30–50 mg daily, based on tolerance and symptom control. 26

Multidisciplinary Management of Refractory Cases

A multidisciplinary team—including primary‑care physicians, gastroenterologists, dietitians, and psychologists—is recommended for patients with severe or refractory functional dyspepsia. 26
Early involvement of a dietitian is advised to avoid overly restrictive diets that could lead to malnutrition. 26
Patients presenting with severe symptoms, weight loss, or restrictive eating patterns should be screened for eating disorders such as avoidant restrictive food intake disorder (ARFID). 26

Management of Functional Dyspepsia with Proton‑Pump Inhibitors

Diagnostic Testing

All individuals diagnosed with functional dyspepsia should undergo non‑invasive Helicobacter pylori testing (13C‑urea breath test or stool antigen preferred over serology) as the initial step, regardless of symptom subtype. 27

First‑Line Pharmacologic Therapy

After H. pylori testing (and eradication if positive), the recommended first‑line pharmacologic treatment is a standard‑dose proton‑pump inhibitor (e.g., omeprazole 20 mg once daily) for 4–8 weeks. 28
In patients who are H. pylori‑negative or who have persistent symptoms after successful eradication, prescribe a standard‑dose PPI (omeprazole 20 mg or equivalent) taken once daily 30–60 minutes before a meal for 4–8 weeks. 27

Eradication of H. pylori

When the H. pylori test is positive, immediate eradication therapy is advised; this eliminates the risk of peptic‑ulcer mortality and provides modest symptom improvement in a minority of functional dyspepsia patients. 28

Age‑Based Management Strategy

Adults ≤55 years without alarm features should receive an H. pylori test‑and‑treat approach followed by empirical PPI therapy if symptoms persist. 27

Cost‑Effectiveness Considerations

Empirical PPI therapy is the most cost‑effective initial approach in populations with low H. pylori prevalence (≤10 %); when prevalence exceeds 10 %, a test‑and‑treat strategy is preferred. 28